CERKL Reduced PI3P/Autophagy to Promote Pancreatic Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Pancreatic cancer (PC) is a significant gastrointestinal malignancy with poorly understood molecular drivers.
• The role of the Ceramide Kinase Like (CERKL) gene in PC pathogenesis remains largely unelucidated.

Purpose of the Study:

• To investigate the expression, function, and regulatory mechanisms of CERKL in pancreatic cancer.
• To identify potential mutations in CERKL and their impact on PC progression.

Main Methods:

• Bioinformatic analysis of online databases for CERKL mRNA expression and mutations in PC.
• In vitro and in vivo studies using cell lines and mouse models to assess CERKL function.
• Investigation of CERKL regulation by E3 ligases and its impact on lipid metabolism and autophagy.
• Analysis of clinical samples for CERKL expression and mutation status.

Main Results:

• CERKL mRNA and protein levels are significantly elevated in PC tissues.
• CERKL promotes PC cell migration and invasion both in vitro and in vivo.
• A novel L296V mutation in CERKL was identified in PC patients, which further enhances migratory and invasive capabilities.
• TRIM21, an E3 ligase, negatively regulates CERKL protein levels and stability; the L296V mutation impairs this interaction.
• CERKL influences phosphatidylinositol levels and regulates autophagy, with the L296V mutation exhibiting a stronger effect.
• Autophagy modulation can impact CERKL-driven metastasis.

Conclusions:

• A novel TRIM21/CERKL/autophagy pathway is implicated in pancreatic cancer progression.
• CERKL, particularly its L296V mutant form, acts as a tumor promoter in PC.
• Targeting CERKL or its regulatory pathways may offer therapeutic strategies for pancreatic cancer.